Search

Researchers at Jagiellonian University in Krakow, Poland, have developed a new nanoparticulate system based on hyaluronic acid for the targeted delivery of sulfasalazine to neuroblastoma. The nanoparticles were surface-modified with PEG chains and glutathione, showing promising results in terms of encapsulation, controlled release, and cytotoxicity against neuroblastoma cells. The study suggests that this delivery system has high potential for neuroblastoma therapy, as indicated by both release profiles and biological studies. This research has been peer-reviewed and published in the European Polymer Journal. [Extracted from the article]

A recent study conducted at Al-Nahrain University in Baghdad, Iraq, compared the anti-inflammatory effects of two drugs, sulfasalazine and ezetimibe, on rats with experimentally induced colitis. The researchers found that both drugs significantly reduced the levels of proinflammatory cytokines in the colon tissue and improved the histopathological score compared to the induced colitis. However, ezetimibe was found to be more effective than sulfasalazine in reducing the inflammatory response. This study suggests that ezetimibe could be a promising treatment option for colitis with fewer adverse effects. [Extracted from the article]

A recent study conducted at North Sichuan Medical College in Sichuan, China, explored the use of co-amorphous systems of sulfasalazine (SULF) with matrine-type alkaloids for the treatment of rheumatoid arthritis (RA). SULF is commonly used to treat RA and inflammatory bowel disease, but its poor water solubility requires high daily doses that can lead to toxic side effects. The researchers found that the co-amorphous systems of SULF with matrine-type alkaloids exhibited enhanced solubility and dissolution performance compared to crystalline SULF. They also identified potential therapeutic targets and synergistic therapeutic mechanisms for the treatment of RA. This study suggests that these co-amorphous systems hold promise for optimizing SULF dosage and providing a potential drug combination strategy in the future. [Extracted from the article]

A patent application has been filed for the use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of rheumatoid arthritis. Rheumatoid arthritis is a chronic inflammatory disease that affects the joints and can lead to pain, swelling, and loss of function. Current treatments for rheumatoid arthritis include disease-modifying antirheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The new treatment aims to provide an effective and potentially safer alternative for managing the symptoms of rheumatoid arthritis. [Extracted from the article]

A recent report from researchers at the University Health Network in Toronto, Canada, compares the retention rates and effectiveness of different treatment strategies for rheumatoid arthritis (RA). The study focused on two commonly used combinations of drugs: triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine, and double therapy with methotrexate and leflunomide. The researchers found that patients on triple therapy remained on treatment longer than those on double therapy, and disease activity was lower in the triple therapy group. However, the difference in retention rates between the two groups was not statistically significant. This research provides valuable insights into the treatment options for RA. [Extracted from the article]

A recent study conducted by Butler University in Indianapolis, Indiana, examined the effect of gastric conditions on the release of mesalamine, a drug used in therapy for gastrointestinal conditions. The study found that the release of the drug was influenced by the presence of food in the stomach. Specifically, the study observed that certain formulations of mesalamine had higher drug release in the presence of food, leading to greater systemic absorption. These findings suggest that in vitro dissolution studies simulating gastric conditions can help predict the impact of food on drug release from modified release mesalamine formulations. [Extracted from the article]

A recent study compared the effectiveness and safety of budesonide and mesalamine in treating microscopic colitis, an inflammatory bowel disease. The study analyzed 19 randomized clinical trials and found that budesonide was associated with higher rates of clinical remission compared to mesalamine, especially after 8 weeks of follow-up. Budesonide also had a lower incidence of adverse events. However, the researchers emphasized the need for further randomized, double-blinded clinical trials to provide more conclusive evidence. [Extracted from the article]

A study conducted at ASZ Aalst focused on distinguishing between a sulfasalazine-induced DRESS hypersensitivity syndrome and a CD30+ lymphoma in a young patient. The patient, a 26-year-old with rheumatoid arthritis, developed DRESS syndrome after sulfasalazine treatment. The study found that the patient's clinical course presented challenges in diagnosing and managing DRESS, emphasizing the need for individualized care, close monitoring, and further research. The research highlights the importance of understanding the underlying mechanisms and optimal therapeutic strategies for DRESS. [Extracted from the article]

A recent study conducted by the Illinois Institute of Technology explores the impact of gut bacteria on the pharmacokinetics of two oral drugs, tacrolimus and sulfasalazine. The researchers found that the presence of certain bacteria can influence the expression of intestinal drug transporters and enzymes, leading to variations in drug bioavailability. Specifically, the study revealed that bacterial modulation reduces the peak blood concentration of tacrolimus but increases the peak plasma concentration of sulfasalazine. These findings suggest that considering the influence of gut bacteria on drug metabolism could improve pharmacokinetic models and address the challenge of variable oral drug bioavailability. [Extracted from the article]

A recent report from the Columbia Institute of Pharmacy discusses the development of novel colon-targeted matrix tablet formulations of mesalamine for the treatment of inflammatory bowel disease (IBD). The researchers used pH-sensitive polymers and biodegradable natural polysaccharides to create the tablets, which were then enteric-coated. The formulations demonstrated the potential to protect the drug from release in the upper gastrointestinal tract while facilitating targeted drug delivery to the colon, potentially improving therapeutic efficacy and minimizing systemic side effects in the treatment of IBD. The study provides valuable insights into the development of localized colonic drug delivery systems. [Extracted from the article]

A recent study conducted by the Department of Physics focused on the theoretical analysis of the anti-inflammatory drug Balsalazide. The researchers used quantum computational calculations and various analytical techniques to examine the molecular structure, electronic properties, and charge distribution of the drug. They also conducted molecular docking studies to investigate how Balsalazide interacts with proteins. The research concluded that Balsalazide exhibits drug-like properties and has potential therapeutic applications. For more information, readers can refer to the original article published in Chemical Physics Impact. [Extracted from the article]

The article discusses a clinical trial focused on juvenile idiopathic arthritis (JIA), the most common chronic rheumatic disease in children. The trial aims to analyze peripheral blood lymphocytes in JIA patients to understand disease subtypes and therapy. It explores different subtypes of JIA, the role of immune system cells in JIA, and available treatments such as NSAIDs, DMARDs, and biologic agents. The trial also examines the potential risk of infections associated with these treatments. It highlights that children with JIA may have a higher risk of infection due to their condition and treatments used, but more research is needed on immune cell alterations related to infection control. [Extracted from the article]

A recent study published in the Research Journal of Pharmacy and Technology highlights the design of colon-specific nanoparticles for the delivery of sulfasalazine, a first-line treatment for Inflammatory Bowel Syndrome. Conventional formulations have poor targeting properties for the colon, so the study aimed to formulate and evaluate polymeric nanoparticles loaded with sulfasalazine to improve therapeutic outcomes. The nanoparticles were prepared using a pH-dependent polymer and evaluated for various properties. The optimized formulation showed satisfactory release and may be suitable for colon targeting of sulfasalazine with improved therapeutic effects. [Extracted from the article]

A study conducted at Djillali Liabes University has explored the use of beeswax-based microparticles for the targeted delivery of mesalamine, a drug used in the treatment of gastrointestinal conditions. The researchers prepared beeswax microparticles and then developed bi-layered microspheres with an enteric coating layer. The formulations were characterized using various techniques, and the drug release was evaluated in simulated gastric, small bowel, and colon liquids. The study concluded by discussing the release mechanism using the Korsmeyer-Peppas model. This research provides insights into the potential of beeswax-based microparticles for colon-specific drug delivery. [Extracted from the article]

A recent study conducted by researchers at Kermanshah University of Medical Sciences in Iran has developed a new drug delivery system for Mesalamine, a commonly used treatment for inflammatory bowel diseases. The system utilizes nanofibers made from a combination of psyllium mucilage and poly(vinyl alcohol) to enhance acid resistance and promote prebiotic activity. The nanofibers demonstrated uniformity, smoothness, and adhesion to the mucosal surface. This multi-effect drug delivery system aims to increase the retention of Mesalamine in the intestine and colon. [Extracted from the article]

A recent report from the University of Nottingham in the United Kingdom discusses the development and validation of a prognostic model for monitoring the toxicity of sulfasalazine, a medication used to treat inflammatory conditions. The study aimed to determine the risk of blood, liver, or kidney toxicity during long-term sulfasalazine treatment. The researchers used data from a retrospective cohort study and developed a risk equation using Cox regression analysis. The model utilizes readily available data and can be used to risk-stratify blood-test monitoring for patients on sulfasalazine treatment. [Extracted from the article]

A recent report from Triserv General Hospital in Taipei, Taiwan, highlights the need for improved treatments for head and neck squamous cell carcinoma (HNSCC), a highly aggressive cancer with a low survival rate. The researchers conducted computational analysis and found that the genes MET, FN1, and TGFBI were significantly upregulated in HNSCC compared to normal samples. These genes are associated with immune infiltration and potential therapeutic resistance. The study also explored the potential of sulfasalazine, an anti-inflammatory drug, as a promising inhibitor of these genes. The findings suggest that sulfasalazine could be used as a standalone therapeutic agent or in combination with cisplatin to counteract drug resistance in HNSCC cells. [Extracted from the article]

A new report from Peking Union Medical College Hospital in Beijing, China discusses the case of a 31-year-old male who was initially suspected to have inflammatory bowel disease (IBD) but was later diagnosed with amebic colitis. The patient's symptoms improved with mesalamine therapy, but the endoscopic ulcers persisted. After two rounds of metronidazole treatment, the patient's condition remained refractory until diloxanide was administered. The research highlights the importance of screening for amebiasis in individuals newly diagnosed with IBD and the cautious use of steroids, especially when mesalamine is not effective. [Extracted from the article]

A recent study conducted by researchers at Islamic Azad University in Yazd, Iran, explored the interaction between sulfasalazine (SSZ) and poly (lactic acid) (PLA) using density functional theory (DFT) and time-dependent density functional theory (TDDFT) methods. The study found that the hydrogen double bond interaction between SSZ and PLA was stronger in state I compared to states II and III. The presence of SSZ also caused a modification in the structure of PLA, as evidenced by both experimental and theoretical Infrared (IR) spectra. The findings suggest that SSZ may enhance the solubility and dipole moment of PLA. [Extracted from the article]

A recent report from researchers at the Universite du Quebec a Montreal provides new insights into mesalamine therapy, a commonly used anti-inflammatory agent for treating Ulcerative Colitis. The study investigates the enzymatic processes involved in the oxidation of mesalamine and its side effects. The researchers found that oxidases, such as ceruloplasmin, peroxidase, and hemoglobin, can recognize mesalamine as a substrate and trigger its oxidation. The study also compared the susceptibility of mesalamine to oxidation with other drugs, such as acetaminophen and salicylic acid. The findings contribute to a better understanding of mesalamine therapy and its potential side effects. [Extracted from the article]

A recent report discusses research on ulcerative colitis, an inflammatory condition of the colon. The study focused on the use of polymer-based mesalamine delayed-release granules (DRGs) for their antioxidant and anti-inflammatory effects in treating ulcerative colitis. The researchers prepared and characterized different types of mesalamine DRGs based on natural polymers like chitosan and pectin. The findings showed that these DRGs effectively delivered mesalamine to the colon and demonstrated significant antioxidant and anti-inflammatory effects in rats with ulcerative colitis. The study suggests that chitosan can be used as a carrier for oral colon delivery of mesalamine in DRG formulation to enhance therapeutic efficacy in ulcerative colitis. [Extracted from the article]

Researchers at Islamic Azad University in Tehran, Iran have developed a new nanocomposite material for drug delivery. The material, made from sodium alginate-zein and modified metal-organic framework, shows promise in improving the bioavailability of sulfasalazine, an antiinfective drug. The researchers characterized the nanocomposite using various techniques and found that it exhibited higher antibacterial activity against gram-positive bacteria compared to sulfasalazine alone. This research provides insight into the development of polymer-modified metal-organic framework-based drug delivery platforms and antibacterial agents. [Extracted from the article]

A recent study conducted by researchers at KLE College of Pharmacy focused on the design, characterization, and stability of mesalamine-loaded solid lipid nanoparticles (MES-SLNs). Solid lipid nanoparticles are used as a carrier system for lipophilic medications to enhance their bioavailability. The researchers used glycerylmonostearate as a lipid, Tween 80 as a surfactant, and cremophor as a solubilizing agent in their formulation. They characterized the formulations using various techniques and found that MES-SLNs were stable at -20°C and 40°C. This study provides valuable insights into the development of nanoparticle-based drug delivery systems. [Extracted from the article]

A recent study conducted in Cleveland, Ohio, examined the use of 5-aminosalicylates (5-ASA) in the treatment of pediatric Crohn's disease (CD). The researchers found that while 5-ASA is commonly used to treat ulcerative colitis, it is not effective in treating CD. The study also found that patients who escalated to biologic therapy did not benefit from continuing 5-ASA treatment. The researchers recommend further studies to confirm these findings. [Extracted from the article]

Keywords: 5-aminosalicylates; Amides; Antiinfectives; Cancer; Carcinomas; Drugs and Therapies; Gastroenterology; Gastrointestinal Agents; Health and Medicine; Oncology; Pharmaceuticals; Radiotherapy; Sulfasalazine; Sulfasalazine Therapy; Sulfonamides EN 5-aminosalicylates Amides Antiinfectives Cancer Carcinomas Drugs and Therapies Gastroenterology Gastrointestinal Agents Health and Medicine Oncology Pharmaceuticals Radiotherapy Sulfasalazine Sulfasalazine Therapy Sulfonamides 1165 1165 1 11/06/23 20231109 NES 231109 2023 NOV 6 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A new study on carcinomas is now available. Sulfasalazine was found to be a cost-effective and safe method for reducing the incidence of radiation-induced acute GI toxicities in cervical carcinoma patients undergoing radiotherapy.". [Extracted from the article]

Acute Hepatitis, Amides, Antiinfectives, Blood Cells, Digestive System Diseases and Conditions, Drugs and Therapies, Eosinophilia, Eosinophils, Gastroenterology, Gastrointestinal Agents, Granulocytes, Health and Medicine, Hematologic Diseases and Conditions, Hemic and Immune Systems, Hepatitis, Immunology, Infectious Diseases and Conditions, Leukocyte Diseases and Conditions, Leukocyte Disorders, Liver Diseases and Conditions, Pharmaceuticals, Sulfasalazine, Sulfasalazine Therapy, Sulfonamides, 5-aminosalicylates Keywords: 5-aminosalicylates; Acute Hepatitis; Amides; Antiinfectives; Blood Cells; Digestive System Diseases and Conditions; Drugs and Therapies; Eosinophilia; Eosinophils; Gastroenterology; Gastrointestinal Agents; Granulocytes; Health and Medicine; Hematologic Diseases and Conditions; Hemic and Immune Systems; Hepatitis; Immunology; Infectious Diseases and Conditions; Leukocyte Diseases and Conditions; Leukocyte Disorders; Liver Diseases and Conditions; Pharmaceuticals; Sulfasalazine; Sulfasalazine Therapy; Sulfonamides EN 5-aminosalicylates Acute Hepatitis Amides Antiinfectives Blood Cells Digestive System Diseases and Conditions Drugs and Therapies Eosinophilia Eosinophils Gastroenterology Gastrointestinal Agents Granulocytes Health and Medicine Hematologic Diseases and Conditions Hemic and Immune Systems Hepatitis Immunology Infectious Diseases and Conditions Leukocyte Diseases and Conditions Leukocyte Disorders Liver Diseases and Conditions Pharmaceuticals Sulfasalazine Sulfasalazine Therapy Sulfonamides 1804 1804 1 10/24/23 20231023 NES 231023 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Hepatitis Weekly -- New study results on acute hepatitis have been published. [Extracted from the article]

Keywords: 5-aminosalicylates; Amides; Antiinfectives; Clinical Research; Clinical Trials and Studies; Dentistry; Dermatology; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Lichen Planus; Lichenoid Eruptions; Mouth Diseases and Conditions; Mouth Diseases and Conditions - Oral Lichen Planus; Oral Lichen Planus; Pharmaceuticals; Skin Diseases and Conditions; Skin and Connective Tissue Diseases and Conditions; Sulfasalazine; Sulfasalazine Therapy; Sulfonamides EN 5-aminosalicylates Amides Antiinfectives Clinical Research Clinical Trials and Studies Dentistry Dermatology Drugs and Therapies Gastrointestinal Agents Health and Medicine Lichen Planus Lichenoid Eruptions Mouth Diseases and Conditions Mouth Diseases and Conditions - Oral Lichen Planus Oral Lichen Planus Pharmaceuticals Skin Diseases and Conditions Skin and Connective Tissue Diseases and Conditions Sulfasalazine Sulfasalazine Therapy Sulfonamides 401 401 1 10/16/23 20231016 NES 231016 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Staff editors report on the newly launched clinical trial, NCT06060301, which has the following summary description: "Oral lichen planus (OLP) is a chronic inflammatory disease that affects the mucosal membrane. Sulfasalazine is extensively used in inflammatory bowel disease and is effective on immune-related inflammatory disease such as Crohn's disease, rheumatoid arthritis, and Behcet's disease. Sulfasalazine is extensively used in inflammatory bowel disease and is effective on immune-related inflammatory disease such as Crohn's disease, rheumatoid arthritis, and Behcet's disease. [Extracted from the article]

In order to match the degradation of drug carriers and their retention time in the colon, a rapidly degradable konjac glucomannan (KGM) hydrogel was designed for colon target drug release. Keywords: 5-aminosalicylates; Alcohols; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Hydrogel; Olsalazine Therapy; Organic Chemicals; Pharmaceuticals; Polyethylene Glycols EN 5-aminosalicylates Alcohols Drugs and Therapies Gastrointestinal Agents Health and Medicine Hydrogel Olsalazine Therapy Organic Chemicals Pharmaceuticals Polyethylene Glycols 2558 2558 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in gastrointestinal agents. [Extracted from the article]

Keywords: Ciudad de Mexico; Mexico; North and Central America; 1-Naphthylamine; 5-aminosalicylates; Antidepressants; Biogenic Amines; Catecholamines; Dopamine; Dopamine Hydrochloride; Drug Delivery; Drug Delivery Systems; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Olsalazine Therapy; Organic Chemicals; Pharmaceuticals; Psychotherapeutic Agents; Selective Serotonin Reuptake Inhibitors; Sertraline; Sertraline Therapy EN Ciudad de Mexico Mexico North and Central America 1-Naphthylamine 5-aminosalicylates Antidepressants Biogenic Amines Catecholamines Dopamine Dopamine Hydrochloride Drug Delivery Drug Delivery Systems Drugs and Therapies Gastrointestinal Agents Health and Medicine Olsalazine Therapy Organic Chemicals Pharmaceuticals Psychotherapeutic Agents Selective Serotonin Reuptake Inhibitors Sertraline Sertraline Therapy 1267 1267 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on Drugs and Therapies - Selective Serotonin Reuptake Inhibitors is now available. According to the news editors, the research concluded: "Due to similarity of systems of dopamine and sertraline with that of phenylethylamine, we conclude that Mg2(olz) is also capable to encapsulate and release these two drugs, being a good proposal as a drug delivery system.". [Extracted from the article]

5-aminosalicylates, Amides, Antiinfectives, Drugs and Therapies, Gastrointestinal Agents, Health and Medicine, Pharmaceuticals, Sulfasalazine, Sulfasalazine Therapy, Sulfonamides Keywords: 5-aminosalicylates; Amides; Antiinfectives; Drugs and Therapies; Gastrointestinal Agents; Health and Medicine; Pharmaceuticals; Sulfasalazine; Sulfasalazine Therapy; Sulfonamides EN 5-aminosalicylates Amides Antiinfectives Drugs and Therapies Gastrointestinal Agents Health and Medicine Pharmaceuticals Sulfasalazine Sulfasalazine Therapy Sulfonamides 941 941 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on antiinfectives have been presented. [Extracted from the article]